Incretin Drug Class: Eli Lilly Likely A Big Beneficiary, As Are Many Other Companies

KKStock I have written several articles regarding the Glp-1 drugs, which I forecast to become the largest-selling pharmaceutical class ever, with 2030 US sales of $150 billion. The benefits of these drugs extend to lessening the chronic diseases associated with obesity that are responsible for significant healthcare spending. These include Type 2 diabetes, cardiovascular disease, obstructive sleep apnea, liver fibrosis, knee osteoarthritis, kidney disease, and possibly several CNS diseases. In fact, Novo No ...